| Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products for the treatment of cardiopulmonary diseases. Co.'s focus is on the development of its nitric oxide therapy for patients with or at risk of pulmonary hypertension (PH) using its proprietary pulsatile nitric oxide delivery platform, INOpulse. INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Co. is developing INOpulse for the treatment of fibrotic interstitial lung disease at risk of PH, PH associated with chronic obstructive pulmonary disease and PH associated with Sarcoidosis. We show 31 historical shares outstanding datapoints in our BLPH shares outstanding history coverage, used to compute BLPH market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BLPH market cap history over the course of time is important for investors
interested in comparing BLPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BLPH versus a peer is one thing; comparing
BLPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BLPH can fluctuate over the course of history.
With this page we aim to empower investors researching BLPH by allowing them to research the BLPH market cap history.